Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Pre-Clinical Studies with D-Penicillamine as a Novel Pharmacological Strategy to Treat Alcoholism: Updated Evidences.

Orrico A, Martí-Prats L, Cano-Cebrián MJ, Granero L, Polache A, Zornoza T.

Front Behav Neurosci. 2017 Mar 7;11:37. doi: 10.3389/fnbeh.2017.00037. eCollection 2017. Review.

2.

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.

Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, Scott C, Koob GF, Litten RZ.

Neuropsychopharmacology. 2017 Apr;42(5):1012-1023. doi: 10.1038/npp.2016.214. Epub 2016 Sep 23.

PMID:
27658483
3.

Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease.

Gitto S, Golfieri L, Caputo F, Grandi S, Andreone P.

Biomolecules. 2016 Jan 15;6(1):11. doi: 10.3390/biom6010011. Review.

4.

Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders.

Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D.

Biol Psychiatry. 2016 Aug 1;80(3):179-89. doi: 10.1016/j.biopsych.2015.10.024. Epub 2015 Nov 17. Review.

5.

Glutamatergic transmission in the central nucleus of the amygdala is selectively altered in Marchigian Sardinian alcohol-preferring rats: Alcohol and CRF effects.

Herman MA, Varodayan FP, Oleata CS, Luu G, Kirson D, Heilig M, Ciccocioppo R, Roberto M.

Neuropharmacology. 2016 Mar;102:21-31. doi: 10.1016/j.neuropharm.2015.10.027. Epub 2015 Oct 28.

6.

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.

Chumakov I, Nabirotchkin S, Cholet N, Milet A, Boucard A, Toulorge D, Pereira Y, Graudens E, Traoré S, Foucquier J, Guedj M, Vial E, Callizot N, Steinschneider R, Maurice T, Bertrand V, Scart-Grès C, Hajj R, Cohen D.

Sci Rep. 2015 Jan 8;5:7608. doi: 10.1038/srep07608.

7.

Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study.

Icro Maremmani AG, Bacciardi S, Rovai L, Rugani F, Massimetti E, Gazzarrini D, Dell'Osso L, Maremmani I.

Int J Environ Res Public Health. 2014 Dec 12;11(12):12983-96. doi: 10.3390/ijerph111212983. Print 2014 Dec.

8.

Change of cystine/glutamate antiporter expression in ethanol-dependent rats.

Peana AT, Muggironi G, Bennardini F.

Front Neurosci. 2014 Oct 6;8:311. doi: 10.3389/fnins.2014.00311. eCollection 2014.

9.

Molecular basis of alcoholism.

Most D, Ferguson L, Harris RA.

Handb Clin Neurol. 2014;125:89-111. doi: 10.1016/B978-0-444-62619-6.00006-9. Review.

10.

Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives.

Pettorruso M, De Risio L, Martinotti G, Di Nicola M, Ruggeri F, Conte G, Di Giannantonio M, Janiri L.

Biomed Res Int. 2014;2014:109786. doi: 10.1155/2014/109786. Epub 2014 Jun 12. Review.

11.

Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.

Wackernah RC, Minnick MJ, Clapp P.

Subst Abuse Rehabil. 2014 Jan 23;5:1-12. doi: 10.2147/SAR.S37907. eCollection 2014. Review.

12.

Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Haass-Koffler CL, Leggio L, Kenna GA.

CNS Drugs. 2014 Apr;28(4):343-60. doi: 10.1007/s40263-014-0149-3. Review.

13.

NMDA Receptor Modulators in the Treatment of Drug Addiction.

Tomek SE, Lacrosse AL, Nemirovsky NE, Olive MF.

Pharmaceuticals (Basel). 2013 Feb 6;6(2):251-68. doi: 10.3390/ph6020251.

14.

Nociceptin/orphanin FQ decreases glutamate transmission and blocks ethanol-induced effects in the central amygdala of naive and ethanol-dependent rats.

Kallupi M, Varodayan FP, Oleata CS, Correia D, Luu G, Roberto M.

Neuropsychopharmacology. 2014 Apr;39(5):1081-92. doi: 10.1038/npp.2013.308. Epub 2013 Oct 30.

15.

Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.

Rubio MD, Drummond JB, Meador-Woodruff JH.

Biomol Ther (Seoul). 2012 Jan;20(1):1-18. doi: 10.4062/biomolther.2012.20.1.001. Review.

16.

Acamprosate produces its anti-relapse effects via calcium.

Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F.

Neuropsychopharmacology. 2014 Mar;39(4):783-91. doi: 10.1038/npp.2013.264. Epub 2013 Sep 30.

17.

Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.

Krishnan-Sarin S, O'Malley S, Krystal JH.

Alcohol Res Health. 2008;31(4):400-7. Review.

18.
19.

mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats.

Sabino V, Narayan AR, Zeric T, Steardo L, Cottone P.

Behav Brain Res. 2013 Jun 15;247:9-16. doi: 10.1016/j.bbr.2013.02.030. Epub 2013 Mar 4.

20.

Management of alcohol dependence in patients with liver disease.

Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R.

CNS Drugs. 2013 Apr;27(4):287-99. doi: 10.1007/s40263-013-0043-4. Review.

Supplemental Content

Support Center